Thrombosis, Cancer, and COVID-19

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2022 May 14

PMID 35567609

Authors

Norman Brito-Dellan

Nikolaos Tsoukalas

Carme Font

Affiliations

Soon will be listed here.

Abstract

Cancer and coronavirus disease 2019 (COVID-19) have unusual similarities: they both result in a markedly elevated risk of thrombosis, exceptionally high D-dimer levels, and the failure of anticoagulation therapy in some cases. Cancer patients are more vulnerable to COVID-19 infection and have a higher mortality rate. Science has uncovered much about SARS-CoV-2, and made extraordinary and unprecedented progress on the development of various treatment strategies and COVID-19 vaccines. In this review, we discuss known data on cancer-associated thrombosis (CAT), SARS-CoV-2 infection, and COVID-19 vaccines and discuss considerations for managing CAT in patients with COVID-19. Cancer patients should be given priority for COVID-19 vaccination; however, they may demonstrate a weaker immune response to COVID-19 vaccines than the general population. Currently, the Centers for Disease Control and Prevention recommends an additional dose and booster shot of the COVID-19 vaccine after the primary series in patients undergoing active cancer treatment for solid tumors or hematological cancers, recipients of stem cell transplant within the last 2 years, those taking immunosuppressive medications, and those undergoing active treatment with high-dose corticosteroids or other drugs that suppress the immune response. The mainstay of thrombosis treatment in patients with cancer and COVID-19 is anticoagulation therapy.

Citing Articles

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera.

Hickey T, Mudunuri U, Hempel H, Kemp T, Roche N, Talsania K Front Immunol. 2025; 15:1502458.

PMID: 39931577 PMC: 11808009. DOI: 10.3389/fimmu.2024.1502458.

The signature of SARS-CoV-2-related genes predicts the immune therapeutic response and prognosis in breast cancer.

Fu R, Chen Y, Zhao J, Xie X BMC Med Genomics. 2024; 17(1):260.

PMID: 39482662 PMC: 11526603. DOI: 10.1186/s12920-024-02032-0.

Thromboembolic events in people with cancer during the COVID-19 pandemic: case-control study.

Lima V, Alves P, Fuly P Rev Lat Am Enfermagem. 2024; 32:e4266.

PMID: 39166625 PMC: 11335067. DOI: 10.1590/1518-8345.7075.4266.

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).

Ortega Moran L, Mateo F, Balanya R, Rogado Revuelta J, Martinez S, Fombella J Clin Transl Oncol. 2024; 26(11):2877-2901.

PMID: 39110395 PMC: 11467034. DOI: 10.1007/s12094-024-03605-2.

Relating D-Dimer, blood sugars, haemoglobin and liver function among COVID patients with T2DM.

Viswanatha Setty B, Nagarajaiah Setty Raghav G, Rangaswamaiah H Bioinformation. 2024; 19(12):1167-1172.

PMID: 38250528 PMC: 10794759. DOI: 10.6026/973206300191167.

References

Thachil J, Khorana A, Carrier M . Similarities and perspectives on the two C's-Cancer and COVID-19. J Thromb Haemost. 2021; 19(5):1161-1167. PMC: 8250039. DOI: 10.1111/jth.15294. View

White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D . Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020; 50(2):287-291. PMC: 7242778. DOI: 10.1007/s11239-020-02145-0. View

Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggin E . COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950-2973. PMC: 7164881. DOI: 10.1016/j.jacc.2020.04.031. View

Lyman G, Khorana A . Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009; 27(29):4821-6. PMC: 2764390. DOI: 10.1200/JCO.2009.22.3032. View

Khorana A, Francis C, Culakova E, Kuderer N, Lyman G . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-4. DOI: 10.1111/j.1538-7836.2007.02374.x. View

Mason D, Quader M, Blackstone E, Rajeswaran J, DeCamp M, Murthy S . Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg. 2006; 131(3):711-8. DOI: 10.1016/j.jtcvs.2005.10.027. View

Hicks L, Cheung M, Ding K, Hasan B, Seymour L, Le Maitre A . Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer. 2009; 115(23):5516-25. DOI: 10.1002/cncr.24596. View

Kuderer N, Ortel T, Francis C . Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27(29):4902-11. PMC: 2799059. DOI: 10.1200/JCO.2009.22.4584. View

Lyman G, Culakova E, Poniewierski M, Kuderer N . Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018; 164 Suppl 1:S112-S118. DOI: 10.1016/j.thromres.2018.01.028. View

10.

Khorana A, McCrae K, Milentijevic D, Laliberte F, Lejeune D, Crivera C . Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. J Med Econ. 2019; 23(4):323-329. DOI: 10.1080/13696998.2019.1703190. View

11.

Benelhaj N, Hutchinson A, Maraveyas A, Seymour J, Ilyas M, Johnson M . Cancer patients' experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis. Palliat Med. 2018; 32(5):1010-1020. DOI: 10.1177/0269216318757133. View

12.

Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horvath-Puho E . Risk of thromboembolic and bleeding outcomes following hematological cancers: A Danish population-based cohort study. J Thromb Haemost. 2019; 17(8):1305-1318. DOI: 10.1111/jth.14475. View

13.

Levi M . Management of cancer-associated disseminated intravascular coagulation. Thromb Res. 2016; 140 Suppl 1:S66-70. DOI: 10.1016/S0049-3848(16)30101-3. View

14.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

15.

Clausen T, Sandoval D, Spliid C, Pihl J, Perrett H, Painter C . SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020; 183(4):1043-1057.e15. PMC: 7489987. DOI: 10.1016/j.cell.2020.09.033. View

16.

Loo J, Spittle D, Newnham M . COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021; 76(4):412-420. DOI: 10.1136/thoraxjnl-2020-216243. View

17.

Gupta A, Madhavan M, Sehgal K, Nair N, Mahajan S, Sehrawat T . Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7):1017-1032. DOI: 10.1038/s41591-020-0968-3. View

18.

Wang J, Jiang M, Chen X, Montaner L . Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020; 108(1):17-41. PMC: 7323250. DOI: 10.1002/JLB.3COVR0520-272R. View

19.

Thalin C, Hisada Y, Lundstrom S, Mackman N, Wallen H . Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. Arterioscler Thromb Vasc Biol. 2019; 39(9):1724-1738. PMC: 6703916. DOI: 10.1161/ATVBAHA.119.312463. View

20.

Manne B, Denorme F, Middleton E, Portier I, Rowley J, Stubben C . Platelet gene expression and function in patients with COVID-19. Blood. 2020; 136(11):1317-1329. PMC: 7483430. DOI: 10.1182/blood.2020007214. View